MSH2 and cancer: A total of 34.8% (n = 31) of participants had a personal history of cancer, including 40.9% (n = 9) of MLH1 carriers, 29.8% (n = 14) of MSH2 carriers, and 40% (n = 8) of MSH6 carriers.